🇺🇸 FDA
Patent

US 8618095

2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses

granted A61PA61P17/02A61P19/02

Quick answer

US patent 8618095 (2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P17/02, A61P19/02, A61P29/00, A61P37/00